ACIP determines guidelines for GlaxoSmithKline, Novartis and Sanofi vaccines

The Advisory Committee on Immunization Practices held a meeting last week to announce its reviews of vaccines from GlaxoSmithKline, Novartis and Sanofi.

The first vaccine on the agenda was Ixiaro, a vaccine developed by Novartis and Intercell Biomedical that protects against encephalitis, a swelling of the brain. The ACIP decided to allow immunization for infants two months of age onward; it was initially only allowed for people 17 years of age and onward, fiercevaccines.com reports.

The next vaccines on the ACIP agenda were booster shots from both GlaxoSmithKline and Sanofi to combat whooping cough. The ACIP decided the cost analysis of using the booster shot would not greatly reduce the rate of disease and decided against it. A follow-up debate has been scheduled.

The last vaccine reviewed was an influenza vaccine from FluBlok. The vaccine uses an insect virus express and recombinant DNA technology. The ACIP decided to recommend the vaccine for people with egg allergies ranging from 18 to 49 years of age.